Hoechst Brings In Major Changes At R U

19 December 1994

Ernst-Gunter Afting, president of Hoechst's French pharmaceutical subsidiary Roussel Uclaf, has resigned and will leave the company on January 31, 1995.

Professor Afting is to be replaced by Jean-Pierre Godard, who currently heads up Hoechst's pharmaceutical division in Frankfurt. Mr Godard is also appointed a vice president and retains his duties at Hoechst.

Hoechst is also bringing in a change in operational structure at Roussel in order to bring it in line with the Hoechst Roussel partnership. The changes affecting human health care operational management will focus on R&D, production, marketing and sales. A joint operational committee will be set up and this will be headed by Mr Godard.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight